Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
- 1 January 2001
- journal article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 32 (3) , 423-432
- https://doi.org/10.1023/a:1017595818158
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Use of recombinant α1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophyPublished by Elsevier ,2003
- Phytotherapy for the prostateBritish Journal of Urology, 1996
- The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic HyperplasiaNew England Journal of Medicine, 1996
- Pharmacological evidence of distinct oci‐adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral arteryBritish Journal of Pharmacology, 1994
- α1-Adrenoceptor classification: sharpening Occam's razorTrends in Pharmacological Sciences, 1994
- New words for old: lower urinary tract symptoms for "prostatism"BMJ, 1994
- Benign Prostatic HyperplasiaDrugs, 1994
- Alfuzosin for treatment of benign prostatic hypertrophyThe Lancet, 1991
- In vitro characterization of the α-adrenoceptors in human prostateEuropean Journal of Pharmacology, 1985
- Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder NeckBritish Journal of Urology, 1975